BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for Retreatment of HCV Infection. N Engl J Med 2011;364:2417-28. [DOI: 10.1056/nejmoa1013086] [Cited by in Crossref: 1157] [Cited by in F6Publishing: 392] [Article Influence: 115.7] [Reference Citation Analysis]
Number Citing Articles
1 Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol 2015; 7(8): 1133-1141 [PMID: 26052402 DOI: 10.4254/wjh.v7.i8.1133] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
2 Strassl R, Rutter K, Stättermayer AF, Beinhardt S, Kammer M, Hofer H, Ferenci P, Popow-Kraupp T. Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy. PLoS One 2015;10:e0135963. [PMID: 26274922 DOI: 10.1371/journal.pone.0135963] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
3 Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, Horvath T, Kennedy GE, Des Jarlais DC. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17:2878-2892. [PMID: 23975473 DOI: 10.1007/s10461-013-0593-y] [Cited by in Crossref: 128] [Cited by in F6Publishing: 112] [Article Influence: 18.3] [Reference Citation Analysis]
4 Ahmad YK, Tawfeek S, Sharaf-Eldin M, Elbatea HE, Kobtan A, El-Kalla F, Badawi R, Abd-Elsalam S. Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hosp Pharm 2017;52:294-301. [PMID: 28515509 DOI: 10.1310/hpj5204-294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397-406. [PMID: 25775312 DOI: 10.7326/m14-1336] [Cited by in Crossref: 242] [Cited by in F6Publishing: 111] [Article Influence: 40.3] [Reference Citation Analysis]
6 Li K, Frankowski KJ, Belon CA, Neuenswander B, Ndjomou J, Hanson AM, Shanahan MA, Schoenen FJ, Blagg BS, Aubé J, Frick DN. Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. J Med Chem 2012;55:3319-30. [PMID: 22409723 DOI: 10.1021/jm300021v] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
7 Naghi SE, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol 2014; 20(16): 4681-4691 [PMID: 24782620 DOI: 10.3748/wjg.v20.i16.4681] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lens S, Calleja JL, Campillo A, Carrión JA, Broquetas T, Perello C, de la Revilla J, Mariño Z, Londoño MC, Sánchez-Tapias JM, Urbano-Ispizua &, Forns X. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. World J Gastroenterol 2015; 21(17): 5421-5426 [PMID: 25954117 DOI: 10.3748/wjg.v21.i17.5421] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: What is the current state - what come’s next? World J Hepatol 2016; 8(3): 139-147 [PMID: 26839638 DOI: 10.4254/wjh.v8.i3.139] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 9.6] [Reference Citation Analysis]
10 Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907-1917. [PMID: 23675659 DOI: 10.1056/nejmra1213651] [Cited by in Crossref: 325] [Cited by in F6Publishing: 161] [Article Influence: 40.6] [Reference Citation Analysis]
11 CLEO Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D’Adamo G, D’Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World J Hepatol 2016; 8(22): 949-956 [PMID: 27574549 DOI: 10.4254/wjh.v8.i22.949] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ogura N, Toyonaga Y, Ando I, Hirahara K, Shibata T, Turcanu G, Pai S, Yee K, Gerhardt B, Rodriguez-Torres M, Noguchi T. Genotypic and phenotypic analyses of hepatitis C virus from patients treated with JTK-853 in a three-day monotherapy. Antimicrob Agents Chemother 2013;57:436-44. [PMID: 23129048 DOI: 10.1128/AAC.01432-12] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group. Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob Agents Chemother 2013;57:4727-35. [PMID: 23856779 DOI: 10.1128/AAC.00565-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
14 Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. PLoS One. 2014;9:e110284. [PMID: 25340799 DOI: 10.1371/journal.pone.0110284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Maasoumy B, Hunyady B, Calvaruso V, Makara M, Vermehren J, Haragh A, Susser S, Bremer B, Cloherty G, Manns MP. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One. 2014;9:e110857. [PMID: 25389779 DOI: 10.1371/journal.pone.0110857] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
16 Molina-Cuadrado E, Mateo-Carrrasco H, Collado A, Casado Martín M. Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. Eur J Hosp Pharm 2018;25:132-7. [PMID: 31157007 DOI: 10.1136/ejhpharm-2017-001277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Klenerman P, Gupta PK. Hepatitis C virus: current concepts and future challenges. QJM 2012;105:29-32. [PMID: 22123990 DOI: 10.1093/qjmed/hcr231] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
18 Iwamoto T, Saeki I, Hidaka I, Ishikawa T, Takami T, Sakaida I. Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report. Am J Case Rep 2019;20:1699-704. [PMID: 31738743 DOI: 10.12659/AJCR.919240] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Lisker-Melman M, Walewski JL. The impact of ethnicity on hepatitis C virus treatment decisions and outcomes. Dig Dis Sci 2013;58:621-9. [PMID: 23065087 DOI: 10.1007/s10620-012-2392-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Neukam K, Morano-Amado LE, Rivero-Juárez A, Macías J, Granados R, Romero-Palacios A, Márquez M, Merino D, Ortega E, Alados-Arboledas JC, Cucurull J, Omar M, Ryan-Murua P, Pineda JA; Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC and Grupo de Estudio de Hepatitis Vírica, of the Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR/Red de Investigación en SIDA (RIS-HEP07). Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. Eur J Clin Microbiol Infect Dis 2017;36:853-61. [PMID: 28004322 DOI: 10.1007/s10096-016-2871-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
21 Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013;75:931-43. [PMID: 22882367 DOI: 10.1111/j.1365-2125.2012.04419.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
22 Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 2012;56:1838-44. [PMID: 22290978 DOI: 10.1128/AAC.05854-11] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
23 Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol 2014; 20(36): 12722-12733 [PMID: 25278674 DOI: 10.3748/wjg.v20.i36.12722] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
24 Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7(12): 1617-1631 [PMID: 26140082 DOI: 10.4254/wjh.v7.i12.1617] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 9.2] [Reference Citation Analysis]
25 Wendt A, Adhoute X, Castellani P, Oules V, Ansaldi C, Benali S, Bourlière M. Chronic hepatitis C: future treatment. Clin Pharmacol. 2014;6:1-17. [PMID: 24470777 DOI: 10.2147/cpaa.s30338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
26 Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170-80. [PMID: 25089861 DOI: 10.7326/M14-0095] [Cited by in Crossref: 107] [Cited by in F6Publishing: 58] [Article Influence: 15.3] [Reference Citation Analysis]
27 Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis 2012;12:324. [PMID: 23181537 DOI: 10.1186/1471-2334-12-324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
28 Sise ME, Backman ES, Wenger JB, Wood BR, Sax PE, Chung RT, Thadhani R, Kim AY. Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study. PLoS One. 2015;10:e0124139. [PMID: 25923243 DOI: 10.1371/journal.pone.0124139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Coen DM, Whitley RJ. Antiviral drugs and antiviral drug resistance. Curr Opin Virol 2011;1:545-7. [PMID: 22440912 DOI: 10.1016/j.coviro.2011.10.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
30 Manvar D, Mishra M, Kumar S, Pandey VN. Identification and evaluation of anti hepatitis C virus phytochemicals from Eclipta alba. J Ethnopharmacol 2012;144:545-54. [PMID: 23026306 DOI: 10.1016/j.jep.2012.09.036] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
31 Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med 2015;7:11-20. [PMID: 25926761 DOI: 10.2147/HMER.S79584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Jothimani D, Chandy GM, Conjeevaram H. A new era in the treatment of chronic hepatitis C infection. Indian J Gastroenterol 2013;32:71-9. [PMID: 23054947 DOI: 10.1007/s12664-012-0254-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A, Touscoz GA, Rizzetto M, Pellicano R, Smedile A. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World J Gastroenterol 2014; 20(36): 13146-13152 [PMID: 25278709 DOI: 10.3748/wjg.v20.i36.13146] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
34 Kirst ME, Li EC, Wang CX, Dong HJ, Liu C, Fried MW, Nelson DR, Wang GP. Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. PLoS One 2013;8:e69698. [PMID: 23922778 DOI: 10.1371/journal.pone.0069698] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
35 Alter HJ, Liang TJ. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med 2012;156:317-8. [PMID: 22351718 DOI: 10.7326/0003-4819-156-4-201202210-00014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
36 Shulla A, Randall G. Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol. 2012;2:725-732. [PMID: 23083892 DOI: 10.1016/j.coviro.2012.09.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
37 Kanda T, Nakamoto S, Wu S, Yokosuka O. Role of IL28B genotype in older hepatitis C virus-infected patients. World J Immunol 2013; 3(3): 54-61 [DOI: 10.5411/wji.v3.i3.54] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 O'Neil CR, Pang JX, Lee SS, Swain MG, Burak KW, Klein P, Myers RP, Kapler J, Gill MJ, Labrie M, Coffin CS. Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients. Can J Infect Dis Med Microbiol 2015;26:293-6. [PMID: 26744584 DOI: 10.1155/2015/974871] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
39 Rajagopalan R, Pan L, Schaefer C, Nicholas J, Lim S, Misialek S, Stevens S, Hooi L, Aleskovski N, Ruhrmund D, Kossen K, Huang L, Yap S, Beigelman L, Serebryany V, Liu J, Sastry S, Seiwert S, Buckman B. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease. Antimicrob Agents Chemother 2017;61:e01569-16. [PMID: 27795376 DOI: 10.1128/AAC.01569-16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
40 Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
41 Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res 2014;6:303-10. [PMID: 24971024 DOI: 10.2147/CEOR.S62092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
42 Stahmeyer JT, Rossol S, Bert F, Böker KH, Bruch HR, Eisenbach C, Link R, John C, Mauss S, Heyne R, Schott E, Pfeiffer-Vornkahl H, Hüppe D, Krauth C. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One 2016;11:e0159976. [PMID: 27467772 DOI: 10.1371/journal.pone.0159976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
43 Claveria-Gimeno R, Vega S, Grazu V, de la Fuente JM, Lanas A, Velazquez-Campoy A, Abian O. Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier. Int J Nanomedicine 2015;10:2249-59. [PMID: 25834436 DOI: 10.2147/IJN.S79480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13:535-542. [PMID: 23743475 DOI: 10.1038/nri3463] [Cited by in Crossref: 106] [Cited by in F6Publishing: 90] [Article Influence: 13.3] [Reference Citation Analysis]
45 Gaite LA, Marciano S, Galdame OA, Gadano AC. Hepatitis C in Argentina: epidemiology and treatment. Hepat Med 2014;6:35-43. [PMID: 24966701 DOI: 10.2147/HMER.S57774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
46 Jazwinski AB, Muir AJ. The horizon: New targets and new agents. Clin Liver Dis (Hoboken) 2012;1:24-7. [PMID: 31186841 DOI: 10.1002/cld.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. PLoS One. 2013;8:e71262. [PMID: 23936497 DOI: 10.1371/journal.pone.0071262] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
48 Saad MF, Alenezi S, Asker H; Kuwait Hepatology Club. Expert opinion on the management of hepatitis C infection in Kuwait. Hepat Med. 2018;10:117-132. [PMID: 30319294 DOI: 10.2147/hmer.s154842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
49 Shinol RC, Gale HB, Kan VL. Performance of the Abbott RealTime HCV Genotype II RUO assay. J Clin Microbiol. 2012;50:3099-3101. [PMID: 22760043 DOI: 10.1128/jcm.01249-12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
50 Brandão R, Marcelino R, Gonçalves F, Diogo I, Carvalho A, Cabanas J, Costa I, Brogueira P, Ventura F, Miranda A, Mansinho K, Gomes P. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018;10:E223. [PMID: 29701642 DOI: 10.3390/v10050223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
51 Kurt R, Chandra PK, Aboulnasr F, Panigrahi R, Ferraris P, Aydin Y, Reiss K, Wu T, Balart LA, Dash S. Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture. PLoS One. 2015;10:e0125962. [PMID: 25961570 DOI: 10.1371/journal.pone.0125962] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
52 O'Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int 2012;25:825-9. [PMID: 22643162 DOI: 10.1111/j.1432-2277.2012.01498.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
53 Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int 2016;10:258-66. [PMID: 26542068 DOI: 10.1007/s12072-015-9668-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
54 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
55 Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virology 2015; 4(3): 178-184 [PMID: 26279979 DOI: 10.5501/wjv.v4.i3.178] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci 2015;60:1045-51. [DOI: 10.1007/s10620-015-3621-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
57 Nishiya AS, de Almeida-Neto C, Ferreira SC, Alencar CS, Di-Lorenzo-Oliveira C, Levi JE, Salles NA, Mendrone A Jr, Sabino EC. HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil. PLoS One 2014;9:e86413. [PMID: 24466079 DOI: 10.1371/journal.pone.0086413] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
58 Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract. 2014;2014:549709. [PMID: 25197269 DOI: 10.1155/2014/549709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Lin CW, Menon R, Liu W, Podsadecki T, Shulman N, DaSilva-Tillmann B, Awni W, Dutta S. Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies. Clin Drug Investig 2017;37:647-57. [PMID: 28378135 DOI: 10.1007/s40261-017-0520-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 Huang X, Deng Z, Long L, Chen J, Tan D, Zhu L, Fan X, Shen T, Lu F. Traceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay. BMC Infect Dis 2016;16:47. [PMID: 26832356 DOI: 10.1186/s12879-016-1390-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Ishida YI, Takeshita M, Kataoka H. Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. World J Hepatol 2014; 6(12): 870-879 [PMID: 25544874 DOI: 10.4254/wjh.v6.i12.870] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
63 Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E. Simeprevir for the treatment of hepatitis C virus infection. Pharmgenomics Pers Med 2014;7:241-9. [PMID: 25206310 DOI: 10.2147/PGPM.S52715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
64 Manns MP, Wedemeyer H, Singer A, Khomutjanskaja N, Dienes HP, Roskams T, Goldin R, Hehnke U, Inoue H. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat. 2012;19:537-546. [PMID: 22762137 DOI: 10.1111/j.1365-2893.2011.01579.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
65 Spindelboeck W, Horvath A, Tawdrous M, Schmerböck B, Zettel G, Posch A, Streit A, Jurse P, Lemesch S, Horn M, Wuensch G, Stiegler P, Stauber RE, Leber B, Stadlbauer V. Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PLoS One 2016;11:e0150299. [PMID: 26938078 DOI: 10.1371/journal.pone.0150299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
66 Brouard C, Boussac-Zarebska M, Silvain C, Durand J, de Lédinghen V, Pillonel J, Delarocque-Astagneau E. Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015. BMC Infect Dis 2017;17:784. [PMID: 29262788 DOI: 10.1186/s12879-017-2889-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
67 Pawlotsky JM. Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection. Clin Liver Dis (Hoboken) 2012;1:58-61. [PMID: 31186849 DOI: 10.1002/cld.8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
68 Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, Bowden R, Spencer CCA, Barnes E, Klenerman P; STOP HCV consortium. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology 2018;68:859-71. [PMID: 29534310 DOI: 10.1002/hep.29877] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
69 Hartman J, Bichoupan K, Patel N, Chekuri S, Harty A, Dieterich D, Perumalswami P, Branch AD. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. World J Gastroenterol 2015; 21(43): 12430-12438 [PMID: 26604650 DOI: 10.3748/wjg.v21.i43.12430] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
70 Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat 2012;2012:138302. [PMID: 23094146 DOI: 10.1155/2012/138302] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Pan Q, Peppelenbosch MP, Janssen HL, Knegt RJ. Telaprevir/boceprevir era: From bench to bed and back. World J Gastroenterol 2012; 18(43): 6183-6188 [PMID: 23180937 DOI: 10.3748/wjg.v18.i43.6183] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
72 Nair DG, Weiskirchen R, Al-Musharafi SK. The use of marine-derived bioactive compounds as potential hepatoprotective agents. Acta Pharmacol Sin 2015;36:158-70. [PMID: 25500871 DOI: 10.1038/aps.2014.114] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
73 Laouénan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Peytavin G, Mentré F, Guedj J. Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients. Antimicrob Agents Chemother 2014;58:5332-41. [PMID: 24982076 DOI: 10.1128/AAC.02611-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
74 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702-726. [PMID: 27130427 DOI: 10.1007/s12072-016-9717-6] [Cited by in Crossref: 141] [Cited by in F6Publishing: 136] [Article Influence: 28.2] [Reference Citation Analysis]
75 Poordad F, Chee GM. Interferon free hepatitis C treatment regimens: the beginning of another era. Curr Gastroenterol Rep 2012;14:74-7. [PMID: 22105465 DOI: 10.1007/s11894-011-0229-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
76 Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, Smith F, van Heeswijk RP. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013;75:431-9. [PMID: 22642697 DOI: 10.1111/j.1365-2125.2012.04345.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
77 Borgia SM, Rowaiye A. Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada. Can J Gastroenterol Hepatol 2015;29:125-9. [PMID: 25855874 DOI: 10.1155/2015/591260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Yu Y, Jing JF, Tong XK, He PL, Li YC, Hu YH, Tang W, Zuo JP. Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. Acta Pharmacol Sin 2014;35:1074-81. [PMID: 25066323 DOI: 10.1038/aps.2014.55] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
79 Sarrazin C, Dierynck I, Cloherty G, Ghys A, Janssen K, Luo D, Witek J, Buti M, Picchio G, De Meyer S. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. J Clin Microbiol 2015;53:1264-9. [PMID: 25653396 DOI: 10.1128/JCM.03030-14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
80 Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 2012;422:174-84. [PMID: 22078164 DOI: 10.1016/j.virol.2011.10.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
81 Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, You S, Remlinger K, Duan M, Kazmierski W. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother. 2014;58:38-47. [PMID: 24126581 DOI: 10.1128/aac.01363-13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
82 He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med 2016;164:84-92. [PMID: 26595252 DOI: 10.7326/M15-0617] [Cited by in Crossref: 109] [Cited by in F6Publishing: 57] [Article Influence: 18.2] [Reference Citation Analysis]
83 Lindgren P, Löfvendahl S, Brådvik G, Weiland O. Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals. J Viral Hepat 2021;28:142-6. [PMID: 32896927 DOI: 10.1111/jvh.13398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Qin H, Li H, Zhou X, Feng F, Shen Y, Tan H, Ye F, Xie Y. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2012;32:665-672. [PMID: 22889114 DOI: 10.1007/bf03261920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
85 Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci 2014;59:3043-52. [PMID: 25102983 DOI: 10.1007/s10620-014-3294-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
86 Werner CR, Franz C, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virol J. 2015;12:37. [PMID: 25889921 DOI: 10.1186/s12985-015-0261-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
87 Bunchorntavakul C, Reddy KR. Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. J Clin Transl Hepatol 2014;2:124-33. [PMID: 26357623 DOI: 10.14218/JCTH.2014.00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
88 Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, Zhang EZ, Tigges AM, Spanks J, Picchio G, Kieffer TL, Sullivan JC. Modeling viral evolutionary dynamics after telaprevir-based treatment. PLoS Comput Biol 2014;10:e1003772. [PMID: 25101970 DOI: 10.1371/journal.pcbi.1003772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
89 Wu E, Yang M, Rao H, Fu S, Feng B, Fei R, Lin A, Fontana RJ, Wei L, Lok AS. Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China. Dig Dis Sci 2017;62:2141-9. [PMID: 28573509 DOI: 10.1007/s10620-017-4619-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544-1553. [PMID: 23152524 DOI: 10.1128/jvi.02294-12] [Cited by in Crossref: 116] [Cited by in F6Publishing: 56] [Article Influence: 12.9] [Reference Citation Analysis]
91 Wendt A, Bourlière M. An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials. Ther Adv Infect Dis 2013;1:191-208. [PMID: 25165553 DOI: 10.1177/2049936113502647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
92 Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol 2014; 20(11): 2876-2887 [PMID: 24659879 DOI: 10.3748/wjg.v20.i11.2876] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
93 Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J; Swiss HIV Cohort Study. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PLoS One 2015;10:e0133028. [PMID: 26176696 DOI: 10.1371/journal.pone.0133028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
94 Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551-561 [PMID: 28469811 DOI: 10.4254/wjh.v9.i11.551] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, Bruce D, Cohen AJ, Bohorquez HE, Carmody I, Loss G, Balart LA, Wu T, Dash S. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One. 2014;9:e108616. [PMID: 25265476 DOI: 10.1371/journal.pone.0108616] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
96 Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015; 7(15): 1953-1963 [PMID: 26244069 DOI: 10.4254/wjh.v7.i15.1953] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
97 Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:268-76. [PMID: 23419289 DOI: 10.1038/nrgastro.2013.17] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
98 Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Koruk ST, Köse Ş, Korkmaz F, Kuruüzüm Z, Tuna N, Taheri S, Sayan M, Demir NA, Sümer Ş, Altınok ES. Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. Balkan Med J 2015;32:266-72. [PMID: 26185714 DOI: 10.5152/balkanmedj.2015.15366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
99 Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. J Gastroenterol 2014;49:737-47. [PMID: 23689988 DOI: 10.1007/s00535-013-0824-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
100 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.7326/0003-4819-156-4-201202210-00005] [Cited by in Crossref: 142] [Cited by in F6Publishing: 138] [Article Influence: 15.8] [Reference Citation Analysis]
101 Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PLoS One 2016;11:e0145409. [PMID: 26752189 DOI: 10.1371/journal.pone.0145409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
102 Barclay ST, Cooke GS, Holtham E, Gauthier A, Schwarzbard J, Atanasov P, Irving WL; HCV Research UK. A new paradigm evaluating cost per cure of HCV infection in the UK. Hepatol Med Policy 2016;1:2. [PMID: 30288304 DOI: 10.1186/s41124-016-0002-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
103 Verna EC, Saxena V, Burton JR, O’Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015;99:1644-1651. [PMID: 25715116 DOI: 10.1097/tp.0000000000000629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
104 Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. J Biol Chem 2015;290:23254-63. [PMID: 26251517 DOI: 10.1074/jbc.M115.662452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Hauser P, Kern S. Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World J Hepatol 2015; 7(15): 1921-1935 [PMID: 26244067 DOI: 10.4254/wjh.v7.i15.1921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
106 Dhiman RK. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? J Clin Exp Hepatol 2014;4:85-6. [PMID: 25755543 DOI: 10.1016/j.jceh.2014.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
107 Ratnoglik SL, Jiang DP, Aoki C, Sudarmono P, Shoji I, Deng L, Hotta H. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities. PLoS One 2014;9:e98877. [PMID: 24901478 DOI: 10.1371/journal.pone.0098877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
108 Brennan BJ, Xu ZX, Grippo JF. Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol. 2013;75:497-506. [PMID: 22765278 DOI: 10.1111/j.1365-2125.2012.04373.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
109 Yap L, Carruthers S, Thompson S, Cheng W, Jones J, Simpson P, Richards A, Thein HH, Haber P, Lloyd A. A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One. 2014;9:e87564. [PMID: 24586281 DOI: 10.1371/journal.pone.0087564] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
110 D'Ambrosio R, Aghemo A. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 2012;12:361-8. [PMID: 22879824 DOI: 10.5812/hepatmon.6095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
111 Hebner CM, Han B, Brendza KM, Nash M, Sulfab M, Tian Y, Hung M, Fung W, Vivian RW, Trenkle J, Taylor J, Bjornson K, Bondy S, Liu X, Link J, Neyts J, Sakowicz R, Zhong W, Tang H, Schmitz U. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One 2012;7:e39163. [PMID: 22720059 DOI: 10.1371/journal.pone.0039163] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
112 Thompson AJ, Holmes JA. Treating hepatitis C - what's new? Aust Prescr 2015;38:191-7. [PMID: 26843711 DOI: 10.18773/austprescr.2015.068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
113 Gambato M, Caro-Pérez N, González P, Cañete N, Mariño Z, Lens S, Bonacci M, Bartres C, Sánchez-Tapias JM, Carrión JA, Forns X, Juan M, Pérez-Del-Pulgar S, Londoño MC. Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. PLoS One 2016;11:e0166631. [PMID: 27861593 DOI: 10.1371/journal.pone.0166631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
114 Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
115 Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174 [PMID: 26290644 DOI: 10.3748/wjg.v21.i30.9163] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
116 Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepat 2015;22:175-83. [PMID: 25040391 DOI: 10.1111/jvh.12278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
117 García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D, Pérez R, Castellano G, González-Portela C. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C. World J Gastroenterol 2013; 19(12): 1943-1952 [PMID: 23569340 DOI: 10.3748/wjg.v19.i12.1943] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
118 Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S, Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatol Int 2016;10:478-87. [PMID: 26886127 DOI: 10.1007/s12072-015-9699-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
119 Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah’moud MA, Abraham GM, Stewart PW. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther. 2015;41:671-685. [PMID: 25627020 DOI: 10.1111/apt.13095] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
120 Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol 2017; 9(5): 252-262 [PMID: 28261382 DOI: 10.4254/wjh.v9.i5.252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
121 Schalasta G, Speicher A, Börner A, Enders M. Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum. J Clin Microbiol 2016;54:1101-7. [PMID: 26865682 DOI: 10.1128/JCM.03236-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
122 Kwo PY, Badshah MB. Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. Curr Gastroenterol Rep 2015;17:462. [PMID: 26342813 DOI: 10.1007/s11894-015-0462-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 De Meyer S, Ghys A, Dierynck I, Beumont M, Luo D, Picchio G. Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virol J. 2014;11:93. [PMID: 24886541 DOI: 10.1186/1743-422x-11-93] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
124 Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, Dusheiko G, Rosenberg WM, Haque T. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. Springerplus 2015;4:357. [PMID: 26191484 DOI: 10.1186/s40064-015-1137-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Sapra S, Chang E, Broder MS, L'Italien G. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Serv Res 2014;14:429. [PMID: 25249187 DOI: 10.1186/1472-6963-14-429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
126 van Heeswijk R, Verboven P, Vandevoorde A, Vinck P, Snoeys J, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Witek J, Garg V. Pharmacokinetic interaction between telaprevir and methadone. Antimicrob Agents Chemother 2013;57:2304-9. [PMID: 23478952 DOI: 10.1128/AAC.02262-12] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
127 Goralczyk AD, Cameron S, Amanzada A. Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients. BMC Gastroenterol 2013;13:148. [PMID: 24118976 DOI: 10.1186/1471-230X-13-148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
128 Vermehren J, Schlosser B, Domke D, Elanjimattom S, Müller C, Hintereder G, Hensel-Wiegel K, Tauber R, Berger A, Haas N. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLoS One. 2012;7:e41206. [PMID: 22848445 DOI: 10.1371/journal.pone.0041206] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
129 Petta S, Craxì A. Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? BMC Infect Dis. 2012;12 Suppl 2:S3. [PMID: 23173606 DOI: 10.1186/1471-2334-12-s2-s3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
130 O’Day R, Gillies MC, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol 2013; 19(45): 8227-8237 [PMID: 24363513 DOI: 10.3748/wjg.v19.i45.8227] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
131 Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med 2016;176:65-73. [PMID: 26595724 DOI: 10.1001/jamainternmed.2015.6011] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 18.8] [Reference Citation Analysis]
132 Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results. PLoS One. 2013;8:e80528. [PMID: 24265827 DOI: 10.1371/journal.pone.0080528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
133 Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669 [PMID: 25276282 DOI: 10.4254/wjh.v6.i9.660] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
134 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
135 Hoffmann L, Ramos JA, Souza EV, Araújo Ramos AL, Villela-Nogueira CA, Urményi TP, Tanuri A, Rondinelli E, Silva R. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J 2013;10:57. [PMID: 23409973 DOI: 10.1186/1743-422X-10-57] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
136 Coburn GA, Fisch DN, Moorji SM, de Muys JM, Murga JD, Paul D, Provoncha KP, Rotshteyn Y, Han AQ, Qian D. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One. 2012;7:e35351. [PMID: 22545104 DOI: 10.1371/journal.pone.0035351] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
137 Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44. [PMID: 21898493 DOI: 10.1002/hep.24641] [Cited by in Crossref: 773] [Cited by in F6Publishing: 710] [Article Influence: 77.3] [Reference Citation Analysis]
138 Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. [PMID: 25002352 DOI: 10.1136/bmj.g3308] [Cited by in Crossref: 142] [Cited by in F6Publishing: 134] [Article Influence: 20.3] [Reference Citation Analysis]
139 Perry CM. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 2012;72:619-641. [PMID: 22439668 DOI: 10.2165/11208370-000000000-00000] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
140 Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Terai S. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. Int J Med Sci 2017;14:403-11. [PMID: 28539815 DOI: 10.7150/ijms.18784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
141 Crosignani A, Riva A, Della Bella S. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016; 22(4): 1393-1404 [PMID: 26819508 DOI: 10.3748/wjg.v22.i4.1393] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
142 Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich D, Branch A. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med. 2014;15:108-115. [PMID: 24025147 DOI: 10.1111/hiv.12086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
143 Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J. Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes 2014;12:90. [PMID: 24915781 DOI: 10.1186/1477-7525-12-90] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
144 Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Nyanguile O, Tahri A, Amssoms K, Lenz O, Cummings MD, Clayton RF, Vendeville S, Raboisson P, Simmen KA, Fanning GC, Lin TI. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother 2012;56:4676-84. [PMID: 22710121 DOI: 10.1128/AAC.00245-12] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
145 Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616 [PMID: 26140081 DOI: 10.4254/wjh.v7.i12.1606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
146 Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W. Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A. J Virol 2013;87:1649-57. [PMID: 23175359 DOI: 10.1128/JVI.02201-12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
147 Pawlotsky JM. New antiviral agents for hepatitis C. F1000 Biol Rep. 2012;4:5. [PMID: 22403588 DOI: 10.3410/b4-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
148 Iijima S, Matsuura K, Watanabe T, Onomoto K, Fujita T, Ito K, Iio E, Miyaki T, Fujiwara K, Shinkai N, Kusakabe A, Endo M, Nojiri S, Joh T, Tanaka Y. Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C. PLoS One 2015;10:e0118000. [PMID: 25706116 DOI: 10.1371/journal.pone.0118000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
149 Pradat P, Virlogeux V, Maynard M, Leclercq M, Hatu G, Amiri M, Lebosse F, Miailhes P, Zoulim F, Gagnieu MC, Bailly F. Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy. Hepat Mon 2015;15:e28879. [PMID: 26500683 DOI: 10.5812/hepatmon.28879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
150 Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190 [PMID: 26839641 DOI: 10.4254/wjh.v8.i3.183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
151 Tamori A, Enomoto M, Kawada N. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm. 2016;2016:6841628. [PMID: 27022210 DOI: 10.1155/2016/6841628] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
152 Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8:e1002832. [PMID: 22910833 DOI: 10.1371/journal.ppat.1002832] [Cited by in Crossref: 149] [Cited by in F6Publishing: 122] [Article Influence: 16.6] [Reference Citation Analysis]
153 Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol 2012;26:205-10. [PMID: 22506260 DOI: 10.1155/2012/751057] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
154 Zitzer H, Heilek G, Truchon K, Susser S, Vermehren J, Sizmann D, Cobb B, Sarrazin C. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol. 2013;51:571-577. [PMID: 23241371 DOI: 10.1128/jcm.01784-12] [Cited by in Crossref: 52] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
155 Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012;5:11-21. [PMID: 22427726 DOI: 10.2147/CEG.S28253] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
156 Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract 2013;19:292-300. [PMID: 23186968 DOI: 10.4158/EP12195.RA] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
157 Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013;16:973-86. [PMID: 24041347 DOI: 10.1016/j.jval.2013.07.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
158 Larrey D, Ripault MP, Pageaux GP. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adherence 2014;8:763-73. [PMID: 24920888 DOI: 10.2147/PPA.S30339] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
159 Caro L, de Hoon J, Depré M, Cilissen C, Miller J, Gao W, Panebianco D, Guo Z, Troemel SL, Anderson MS, Uemura N, Butterton J, Wagner J, Wright DH. Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men. Clin Transl Sci 2017;10:480-6. [PMID: 28796416 DOI: 10.1111/cts.12482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig 2013;33:325-31. [PMID: 23532802 DOI: 10.1007/s40261-013-0074-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
161 Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One 2014;9:e90295. [PMID: 24603445 DOI: 10.1371/journal.pone.0090295] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
162 Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology. 2014;60:1187-1195. [PMID: 25065814 DOI: 10.1002/hep.27340] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
163 Schneider MD, Sarrazin C. Management of HCV-Associated Liver Cirrhosis. Visc Med 2016;32:96-104. [PMID: 27413726 DOI: 10.1159/000445330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
164 Shadrick WR, Mukherjee S, Hanson AM, Sweeney NL, Frick DN. Aurintricarboxylic acid modulates the affinity of hepatitis C virus NS3 helicase for both nucleic acid and ATP. Biochemistry 2013;52:6151-9. [PMID: 23947785 DOI: 10.1021/bi4006495] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
165 Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int 2014;34:1018-24. [PMID: 24118693 DOI: 10.1111/liv.12342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
166 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.1059/0003-4819-156-4-201202210-00005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L; ANRS CO20-CUPIC study group. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PLoS One 2015;10:e0145105. [PMID: 26670100 DOI: 10.1371/journal.pone.0145105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
168 Chen JY, Chung RT. Future classes of hepatitis C virus therapeutic agents. Infect Dis Clin North Am 2012;26:949-66. [PMID: 23083826 DOI: 10.1016/j.idc.2012.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Lepida A, Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Mangia A, Calleja JL, Iraqi W, DeMasi R, Lonjon-Domanec I, Moreno C, Wedemeyer H. Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLoS One 2015;10:e0138503. [PMID: 26398503 DOI: 10.1371/journal.pone.0138503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
170 Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083-2091. [PMID: 24604476 DOI: 10.1002/hep.27113] [Cited by in Crossref: 445] [Cited by in F6Publishing: 388] [Article Influence: 63.6] [Reference Citation Analysis]
171 Sockalingam S, Tseng A, Giguere P, Wong D. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol. 2013;13:86. [PMID: 23672254 DOI: 10.1186/1471-230x-13-86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
172 Lee A, Rajanayagam J, Abdel-Hady M. Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies. J Clin Transl Hepatol 2015;3:36-41. [PMID: 26357633 DOI: 10.14218/JCTH.2014.00036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
173 Lin MV, Charlton AN, Rouster SD, Zamor PJ, Sherman KE. Hepatitis C virus NS3 mutations in haemophiliacs. Haemophilia 2014;20:659-65. [PMID: 24697920 DOI: 10.1111/hae.12420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
174 Tovo CV, Mattos AA, Almeida PRL. Chronic hepatitis C genotype 1 virus: Who should wait for treatment? World J Gastroenterol 2014; 20(11): 2867-2875 [PMID: 24659878 DOI: 10.3748/wjg.v20.i11.2867] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
175 Susser S, Flinders M, Reesink HW, Zeuzem S, Lawyer G, Ghys A, Van Eygen V, Witek J, De Meyer S, Sarrazin C. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir. Antimicrob Agents Chemother 2015;59:2746-55. [PMID: 25712364 DOI: 10.1128/AAC.04911-14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
176 Yeung CY, Lee HC, Chan WT, Jiang CB, Chang SW, Chuang CK. Vertical transmission of hepatitis C virus: Current knowledge and perspectives. World J Hepatol 2014; 6(9): 643-651 [PMID: 25276280 DOI: 10.4254/wjh.v6.i9.643] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
177 Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother 2013;57:6236-45. [PMID: 24100495 DOI: 10.1128/AAC.01578-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
178 Bogdanović Z, Marinović-Terzić I, Kuret S, Jerončić A, Bradarić N, Forempoher G, Polašek O, Anđelinović Š, Terzić J. The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. PeerJ 2016;4:e2576. [PMID: 27812403 DOI: 10.7717/peerj.2576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
179 Deutsch L, Houri I, Ben-Ari Z, Shlomai A, Veitsman E, Cohen-Ezra O, Issachar A, Mor O, Gozlan Y, Bruck R, Menachem Y, Zelber-Sagi S, Katchman H, Shibolet O. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. BMC Infect Dis 2020;20:264. [PMID: 32245397 DOI: 10.1186/s12879-020-4921-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
180 Susser S, Herrmann E, Lange C, Hamdi N, Müller T, Berg T, Perner D, Zeuzem S, Sarrazin C. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One 2014;9:e112592. [PMID: 25393304 DOI: 10.1371/journal.pone.0112592] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
181 Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver Int 2015;35:2358-62. [PMID: 26248955 DOI: 10.1111/liv.12931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
182 Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124-1135. [PMID: 25687730 DOI: 10.1016/s0140-6736(14)62401-6] [Cited by in Crossref: 335] [Cited by in F6Publishing: 141] [Article Influence: 55.8] [Reference Citation Analysis]
183 Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One. 2014;9:e94542. [PMID: 24728219 DOI: 10.1371/journal.pone.0094542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
184 Akbar HO, Al Ghamdi A, Qattan F, Fallatah HI, Al Rumani M. Chronic hepatitis C in saudi arabia: three years local experience in a university hospital. Hepat Mon 2012;12:e6178. [PMID: 23087760 DOI: 10.5812/hepatmon.6178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
185 Bota S, Sporea I, Şirli R, Popescu A, Neghină AM, Dănilă M, Străin M. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World J Hepatol 2013; 5(3): 120-126 [PMID: 23556044 DOI: 10.4254/wjh.v5.i3.120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
186 Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, Kleiner DE, Rotman Y, Ghany MG, Liang TJ, Hoofnagle JH. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887-94. [PMID: 23461575 DOI: 10.1111/apt.12273] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
187 Yang D, Meng X, Yu Q, Xu L, Long Y, Liu B, Fang X, Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein. Antimicrob Agents Chemother. 2013;57:4937-4944. [PMID: 23877701 DOI: 10.1128/aac.00897-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
188 Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, Raven JF, Roberts E, Choucha N, Myers RP, Sagan SM, Wilson JA, Bialystok F, Tyrrell DL, Houghton M, Krajden M; National CIHR Research Training Program in Hepatitis C. The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol 2013;27:627-32. [PMID: 24199209 DOI: 10.1155/2013/242405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
189 Echeverría N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. World J Hepatol 2015; 7(6): 831-845 [PMID: 25937861 DOI: 10.4254/wjh.v7.i6.831] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
190 Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, Zimmermann T. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. Drug Des Devel Ther 2017;11:2131-8. [PMID: 28744104 DOI: 10.2147/DDDT.S139837] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
191 Manvar D, Singh K, Pandey VN. Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site. Biochemistry 2013;52:432-44. [PMID: 23268692 DOI: 10.1021/bi301098g] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
192 Hanson AM, Hernandez JJ, Shadrick WR, Frick DN. Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase. Methods Enzymol 2012;511:463-83. [PMID: 22713333 DOI: 10.1016/B978-0-12-396546-2.00021-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
193 Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. 2014;6:4-15. [PMID: 24106239 DOI: 10.1002/emmm.201303131] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
194 Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127 [PMID: 29290649 DOI: 10.3748/wjg.v23.i46.8120] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
195 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
196 Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, Bhagani S, López-Cortés LF, Haberl A, Stoeckle M. Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. PLoS One. 2015;10:e0125080. [PMID: 25923540 DOI: 10.1371/journal.pone.0125080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
197 Moritou Y, Ikeda F, Iwasaki Y, Baba N, Takaguchi K, Senoh T, Nagano T, Takeuchi Y, Yasunaka T, Ohnishi H. Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C. Springerplus. 2013;2:251. [PMID: 23772356 DOI: 10.1186/2193-1801-2-251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
198 Tamborini Permunian E, Gervaso L, Gerdes V, Moja L, Guasti L, Squizzato A. Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. Intern Emerg Med 2018;13:775-90. [PMID: 29611106 DOI: 10.1007/s11739-018-1828-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
199 Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72 [PMID: 29147645 DOI: 10.5501/wjv.v6.i4.59] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
200 Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
201 Dresch KF, Mattos AA, Tovo CV, Onofrio FQ, Casagrande L, Feltrin AA, Barros IC, Almeida PR. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. Rev Inst Med Trop Sao Paulo 2016;58:37. [PMID: 27253739 DOI: 10.1590/S1678-9946201658037] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
202 Deval J, Symons JA, Beigelman L. Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus. Curr Opin Virol 2014;9:1-7. [PMID: 25194816 DOI: 10.1016/j.coviro.2014.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
203 Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401 [PMID: 27605875 DOI: 10.3748/wjg.v22.i28.6393] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
204 Mesalam AA, Vercauteren K, Meuleman P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses 2016;8:E176. [PMID: 27338446 DOI: 10.3390/v8060176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
205 Toyota J, Ozeki I, Karino Y, Asahina Y, Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, Suzuki Y, Suzuki F, Kumada H. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat 2013;20:167-73. [PMID: 23383655 DOI: 10.1111/j.1365-2893.2012.01640.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
206 Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6:4-14. [PMID: 25553238 DOI: 10.1177/2040622314551934] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
207 Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One. 2013;8:e55285. [PMID: 23383319 DOI: 10.1371/journal.pone.0055285] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 9.6] [Reference Citation Analysis]
208 Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013;13:190. [PMID: 23621902 DOI: 10.1186/1471-2334-13-190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
209 Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations. Antimicrob Agents Chemother 2013;57:4417-26. [PMID: 23836176 DOI: 10.1128/AAC.00399-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
210 Carvalho-Filho RJ, Feldner ACC, Silva AEB, Ferraz MLG. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol 2015; 21(2): 408-422 [PMID: 25593456 DOI: 10.3748/wjg.v21.i2.408] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
211 El-Guindi MA. Hepatitis C Viral Infection in Children: Updated Review. Pediatr Gastroenterol Hepatol Nutr 2016;19:83-95. [PMID: 27437184 DOI: 10.5223/pghn.2016.19.2.83] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
212 Bowring MG, Kucirka LM, Massie AB, Luo X, Cameron A, Sulkowski M, Rakestraw K, Gurakar A, Kuo I, Segev DL, Durand CM. Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. Am J Transplant. 2017;17:519-527. [PMID: 27456927 DOI: 10.1111/ajt.13976] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 12.8] [Reference Citation Analysis]
213 Zhong QF, Liu R, Liu G. Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. Mol Divers 2015;19:829-53. [PMID: 26205408 DOI: 10.1007/s11030-015-9610-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
215 Al-Hamoudi WK. Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol 2016;22:173-82. [PMID: 27184634 DOI: 10.4103/1319-3767.182453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Laouénan C, Guedj J, Peytavin G, Nguyen TT, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Marcellin P, Mentré F. A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy. CPT Pharmacometrics Syst Pharmacol 2015;4:e00008. [PMID: 26225222 DOI: 10.1002/psp4.8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
217 Chen YC, Bernaards C, Kulkarni R, Moreira S, Zhu Y, Chan A, Badman E, Ackrill A, Thommes J, Smith PF. Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies. Br J Clin Pharmacol 2014;78:533-42. [PMID: 24602156 DOI: 10.1111/bcp.12369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
218 Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:596-606. [PMID: 23817323 DOI: 10.1038/nrgastro.2013.106] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 12.0] [Reference Citation Analysis]
219 Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep 2016;6:22995. [PMID: 26965318 DOI: 10.1038/srep22995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
220 Borba HH, Wiens A, Steimbach LM, Tonin FS, Pedroso M, Ivantes CA, Fernandez-Llimos F, Pontarolo R. Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Ther Clin Risk Manag 2017;13:59-64. [PMID: 28138248 DOI: 10.2147/TCRM.S124663] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
221 Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Aizawa Y. Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. J Postgrad Med 2016;62:20-5. [PMID: 26732192 DOI: 10.4103/0022-3859.173191] [Reference Citation Analysis]
222 Humphries K, Darling JM, Barritt AS 4th. Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature. Dig Dis Sci 2014;59:2007-12. [PMID: 24633573 DOI: 10.1007/s10620-014-3085-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
223 Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virology 2015; 4(1): 1-12 [PMID: 25674512 DOI: 10.5501/wjv.v4.i1.1] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
224 Aouri M, Moradpour D, Cavassini M, Mercier T, Buclin T, Csajka C, Telenti A, Rauch A, Decosterd LA. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrob Agents Chemother 2013;57:3147-58. [PMID: 23629707 DOI: 10.1128/AAC.00281-13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
225 Ciotti M, D'Agostini C, Marrone A. Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. Gastroenterology Res 2013;6:161-70. [PMID: 27785248 DOI: 10.4021/gr576e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
226 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
227 Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, Sane RS. Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 2015;59:25-37. [PMID: 25313217 DOI: 10.1128/AAC.03861-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
228 Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015; 7(5): 725-737 [PMID: 25914773 DOI: 10.4254/wjh.v7.i5.725] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
229 Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 2014;58:2781-97. [PMID: 24590484 DOI: 10.1128/AAC.02386-13] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 5.9] [Reference Citation Analysis]
230 Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34. [PMID: 25585348 DOI: 10.1155/2015/692408] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
231 Fénéant L, Levy S, Cocquerel L. CD81 and hepatitis C virus (HCV) infection. Viruses 2014;6:535-72. [PMID: 24509809 DOI: 10.3390/v6020535] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
232 Salloum S, Tai AW. Treating hepatitis C infection by targeting the host. Transl Res 2012;159:421-9. [PMID: 22633094 DOI: 10.1016/j.trsl.2011.12.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
233 Garbuglia AR, Visco-Comandini U, Lionetti R, Lapa D, Castiglione F, D'Offizi G, Taibi C, Montalbano M, Capobianchi MR, Paci P. Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. PLoS One 2016;11:e0158989. [PMID: 27560794 DOI: 10.1371/journal.pone.0158989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
234 Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Müllhaupt B, Bochud PY; Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013;210:1109-16. [PMID: 23712427 DOI: 10.1084/jem.20130012] [Cited by in Crossref: 161] [Cited by in F6Publishing: 158] [Article Influence: 20.1] [Reference Citation Analysis]
235 Indolfi G, Azzari C, Resti M. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: From adults to children. World J Gastroenterol 2014; 20(28): 9245-9252 [PMID: 25071317 DOI: 10.3748/wjg.v20.i28.9245] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
236 Ma H, Le Pogam S, Fletcher S, Hinojosa-Kirschenbaum F, Javanbakht H, Yan JM, Jiang WR, Inocencio N, Klumpp K, Nájera I. Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination. Antimicrob Agents Chemother 2014;58:2614-25. [PMID: 24550342 DOI: 10.1128/AAC.02250-13] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
237 Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int. 2012;109:352-358. [PMID: 22675406 DOI: 10.3238/arztebl.2012.0352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
238 Cartwright EJ, Miller L. Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Hepatic Medicine: Evidence and Research. 2013;5:53-61. [PMID: 24696624 DOI: 10.2147/hmer.s48545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
239 Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol 2013;24:217-38. [PMID: 24489565 DOI: 10.1155/2013/781410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
240 Enomoto H, Nishiguchi S. Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. World J Hepatol 2015; 7(26): 2681-2687 [PMID: 26609345 DOI: 10.4254/wjh.v7.i26.2681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
241 Gomes LO, Teixeira MR, Rosa JAD, Feltrin AA, Rodrigues JPV, Vecchi MD, Carneiro JMM, Noblat LACB, Chachá SGF, Martinelli ALC, Pereira LRL, Silveira MPT, Blatt CR, Farias MR. Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir. Rev Inst Med Trop Sao Paulo 2018;60:e29. [PMID: 29972466 DOI: 10.1590/s1678-9946201860029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
242 Al-Judaibi B. The new era of hepatitis C virus therapy. Saudi J Gastroenterol 2015;21:345-54. [PMID: 26655128 DOI: 10.4103/1319-3767.170947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
243 Poordad F, Rustgi V, Brown RS Jr, Patel V, Kugelmas M, Regenstein F, Balart L, LaBrecque D, Brown K, Avila M, Biederman M, Freed G, Smith R, Bernstein M, Arnold H, Cahan J, Fink S, Katkov W, Massoumi H, Harrison S. The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). Therap Adv Gastroenterol 2015;8:263-9. [PMID: 26327916 DOI: 10.1177/1756283X15588876] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
244 Sharma SA, Feld JJ. Management of HCV in cirrhosis-a rapidly evolving landscape. Curr Gastroenterol Rep 2015;17:443. [PMID: 25896437 DOI: 10.1007/s11894-015-0443-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
245 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143. [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
246 Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS One 2012;7:e52158. [PMID: 23284915 DOI: 10.1371/journal.pone.0052158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
247 Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol 2015; 7(1): 78-92 [PMID: 25624999 DOI: 10.4254/wjh.v7.i1.78] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
248 Colombo M, Fernández I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Moreno C, Streinu-Cercel A, Verheyen A, Iraqi W, DeMasi R, Hill A, Läuffer JM, Lonjon-Domanec I, Wedemeyer H. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 2014;63:1150-8. [PMID: 24201995 DOI: 10.1136/gutjnl-2013-305667] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
249 KayvanJoo AH, Ebrahimi M, Haqshenas G. Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms. BMC Res Notes 2014;7:565. [PMID: 25150834 DOI: 10.1186/1756-0500-7-565] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
250 Chen LZ, Rose P, Mao Y, Yong CL, St George R, Huang F, Latli B, Mandarino D, Li Y. Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother 2014;58:2369-76. [PMID: 24514093 DOI: 10.1128/AAC.02156-13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
251 Salam KA, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, Moriishi K, Nakakoshi M, Tani H, Roy SR, Tanaka J, Tsubuki M, Akimitsu N. PBDE: structure-activity studies for the inhibition of hepatitis C virus NS3 helicase. Molecules 2014;19:4006-20. [PMID: 24699145 DOI: 10.3390/molecules19044006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
252 Kanda T, Nakamoto S, Nakamura M, Jiang X, Miyamura T, Wu S, Yokosuka O. Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. J Clin Transl Hepatol. 2014;2:1-6. [PMID: 26356295 DOI: 10.14218/jcth.2013.00025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
253 Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt-Yilmaz N, Schiffer CA, Ali A. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. J Med Chem 2017;60:5699-716. [PMID: 28594175 DOI: 10.1021/acs.jmedchem.7b00426] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
254 Kretzer IF, do Livramento A, da Cunha J, Gonçalves S, Tosin I, Spada C, Treitinger A. Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment. ScientificWorldJournal. 2014;2014:827849. [PMID: 25013871 DOI: 10.1155/2014/827849] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
255 Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One. 2012;7:e34372. [PMID: 22511937 DOI: 10.1371/journal.pone.0034372] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 7.6] [Reference Citation Analysis]
256 Kanda T, Yokosuka O, Omata M. Treatment of hepatitis C virus infection in the future. Clin Transl Med. 2013;2:9. [PMID: 23577631 DOI: 10.1186/2001-1326-2-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
257 Shindoh J, Hasegawa K, Takemura N, Omichi K, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Kokudo N. Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus. Hepatol Int 2014;8:112-20. [PMID: 26202412 DOI: 10.1007/s12072-013-9507-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
258 Chae HB, Park SM, Youn SJ. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. ScientificWorldJournal 2013;2013:704912. [PMID: 23844410 DOI: 10.1155/2013/704912] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
259 Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941-953. [PMID: 24626851 DOI: 10.1007/s00535-014-0949-8] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
260 Wilder JM, Muir AJ. Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis. 2015;6:314-327. [PMID: 26568808 DOI: 10.1177/2040622315603642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
261 Nguyen TH, Guedj J, Yu J, Levi M, Mentré F. Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome. CPT Pharmacometrics Syst Pharmacol 2013;2:e56. [PMID: 23863865 DOI: 10.1038/psp.2013.31] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
262 Gardiner CM. NK cell function and receptor diversity in the context of HCV infection. Front Microbiol 2015;6:1061. [PMID: 26483779 DOI: 10.3389/fmicb.2015.01061] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
263 Kobayashi T, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 2013;43:1347-54. [DOI: 10.1007/s00595-012-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
264 Nakayama M, Kobayashi H, Fukushima K, Ishido M, Komada Y, Yoshizawa K. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatol Int 2016;10:158-68. [PMID: 26264253 DOI: 10.1007/s12072-015-9654-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
265 Cunningham M, Foster GR. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol 2012;5:139-51. [PMID: 22423262 DOI: 10.1177/1756283X11426895] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
266 Haseltine EL, Kimko H, Luo H, Tolsma J, Bartels DJ, Kieffer TL, Garg V. Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies. J Pharmacokinet Pharmacodyn 2015;42:681-98. [PMID: 26289844 DOI: 10.1007/s10928-015-9435-z] [Reference Citation Analysis]
267 Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruíz-Pacheco JA, Cazares F, Vaughan G. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol 2012;50:281-7. [PMID: 22116161 DOI: 10.1128/JCM.05842-11] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
268 Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl. 2012;18:1053-1059. [PMID: 22706796 DOI: 10.1002/lt.23482] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
269 Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014;60:872-84. [PMID: 24280292 DOI: 10.1016/j.jhep.2013.11.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
270 Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One 2017;12:e0169401. [PMID: 28046099 DOI: 10.1371/journal.pone.0169401] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
271 Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O’Regan C, Mills EJ. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag. 2012;8:105-130. [PMID: 22442631 DOI: 10.2147/tcrm.s29830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
272 Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20(29): 9633-9652 [PMID: 25110404 DOI: 10.3748/wjg.v20.i29.9633] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 80] [Article Influence: 13.7] [Reference Citation Analysis]
273 Toshikuni N. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut Liver 2017;11:335-48. [PMID: 27840363 DOI: 10.5009/gnl15458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
274 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
275 Liu B, McGilvray I, Chen L. IFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. Gastroenterol Res Pract 2015;2015:796461. [PMID: 26078754 DOI: 10.1155/2015/796461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
276 Chuang WL, Yu ML. Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol. 2013;48:22-30. [PMID: 23104468 DOI: 10.1007/s00535-012-0669-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
277 Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther 2014;39:209-16. [PMID: 24266536 DOI: 10.1111/apt.12560] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
278 Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, Miyamura T, Maruoka D, Wu S, Tanaka T. Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy. Int J Med Sci. 2013;10:43-49. [PMID: 23289004 DOI: 10.7150/ijms.5383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
279 徐庆年, 杨宗国, 陆云飞, 陈晓蓉. 聚乙二醇干扰素联合利巴韦林治疗经治慢性丙型肝炎患者的回顾性分析. 世界华人消化杂志 2013; 21(19): 1797-1802 [DOI: 10.11569/wcjd.v21.i19.1797] [Reference Citation Analysis]
280 Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS 2014;28:365-76. [PMID: 24670522 DOI: 10.1097/QAD.0000000000000093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
281 Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012;57:946-952. [PMID: 22760009 DOI: 10.1016/j.jhep.2012.06.030] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
282 Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM. 2013;106:153-163. [PMID: 23159839 DOI: 10.1093/qjmed/hcs214] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
283 Berden FA, de Knegt RJ, Blokzijl H, Kuiken SD, van Erpecum KJ, Willemse SB, den Hollander J, van Vonderen MG, Friederich P, van Hoek B, van Nieuwkerk CM, Drenth JP, Kievit W. Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS One 2016;11:e0161821. [PMID: 27598789 DOI: 10.1371/journal.pone.0161821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
284 Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Ups J Med Sci 2018;123:50-6. [PMID: 29536805 DOI: 10.1080/03009734.2018.1441928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
285 Upadya MH, Aweya JJ, Tan YJ. Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. World J Gastroenterol 2014; 20(11): 2913-2926 [PMID: 24659882 DOI: 10.3748/wjg.v20.i11.2913] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
286 Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 2015;59:988-97. [PMID: 25451053 DOI: 10.1128/AAC.04227-14] [Cited by in Crossref: 90] [Cited by in F6Publishing: 49] [Article Influence: 12.9] [Reference Citation Analysis]
287 Stein J, Connor S, Virgin G, Ong DEH, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol 2016; 22(35): 7908-7925 [PMID: 27672287 DOI: 10.3748/wjg.v22.i35.7908] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 40] [Article Influence: 11.6] [Reference Citation Analysis]
288 Gray E, Pasta DJ, Norris S, O'Leary A; Irish Hepatitis C Outcomes and Research Network (ICORN). Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. BMC Health Serv Res 2017;17:288. [PMID: 28424064 DOI: 10.1186/s12913-017-2188-1] [Reference Citation Analysis]
289 Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015;7:5018-39. [PMID: 26389941 DOI: 10.3390/v7092857] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
290 Janczewska E, Zarębska-Michaluk D, Berak H, Piekarska A, Gietka A, Dybowska D, Mazur W, Belica-Wdowik T, Dobracki W, Tudrujek-Zdunek M, Deroń Z, Buczyńska I, Sitko M, Czauż-Andrzejuk A, Lorenc B, Białkowska-Warzecha J, Citko J, Laurans Ł, Jaroszewicz J, Socha Ł, Tronina O, Adamek B, Horban A, Halota W, Baka-Ćwierz B, Tomasiewicz K, Simon K, Garlicki A, Wawrzynowicz-Syczewska M, Flisiak R. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. BMC Infect Dis 2018;18:580. [PMID: 30445916 DOI: 10.1186/s12879-018-3465-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
291 Flisiak R, Shiffman M, Arenas J, Cheinquer H, Nikitin I, Dong Y, Rana K, Srinivasan S. A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C. PLoS One 2016;11:e0164563. [PMID: 27749900 DOI: 10.1371/journal.pone.0164563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
292 Yang D, Meng X, Yu Q, Xu L, Long Y, Liu B, Fang X, Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein. Antimicrob Agents Chemother. 2013;57:4937-4944. [PMID: 23877701 DOI: 10.1128/aac.00897] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
293 Flores-Contreras L, Sandoval-Rodríguez AS, Mena-Enriquez MG, Lucano-Landeros S, Arellano-Olivera I, Alvarez-Álvarez A, Sanchez-Parada MG, Armendáriz-Borunda J. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol 2014;14:131. [PMID: 25064094 DOI: 10.1186/1471-230X-14-131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
294 Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D; Swiss Hepatitis C Cohort Study Group. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One 2012;7:e40159. [PMID: 22808108 DOI: 10.1371/journal.pone.0040159] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
295 Kanda T, Yokosuka O, Omata M. Faldaprevir for the treatment of hepatitis C. Int J Mol Sci. 2015;16:4985-4996. [PMID: 25749475 DOI: 10.3390/ijms16034985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
296 Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015;60:573-581. [PMID: 25236421 DOI: 10.1007/s10620-014-3361-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
297 Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud PY, Negro F, Pawlotsky JM, Zeuzem S, Ferrari C, Norkrans G, Wejstål R, Westin J, Neumann AU, Haagmans BL, Lindh M, Missale G, Hellstrand K, Lagging M. Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. PLoS One 2013;8:e56991. [PMID: 23437290 DOI: 10.1371/journal.pone.0056991] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
298 Miotto N, Mendes LC, Zanaga LP, Goncales ES, Lazarini MS, Pedro MN, Goncales FL Jr, Stucchi RS, Vigani AG. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Braz J Med Biol Res 2016;49:S0100-879X2016000700702. [PMID: 27356107 DOI: 10.1590/1414-431X20165300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
299 Litwin AH, Soloway IJ, Cockerham-Colas L, Reynoso S, Heo M, Tenore C, Roose RJ. Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. Int J Drug Policy 2015;26:1014-9. [PMID: 26341685 DOI: 10.1016/j.drugpo.2015.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
300 Nam HC, Lee HL, Yang H, Song MJ. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. Clin Mol Hepatol 2016;22:259-66. [PMID: 27377910 DOI: 10.3350/cmh.2016.0020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
301 Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother. 2011;55:4569-4574. [PMID: 21825288 DOI: 10.1128/aac.00653-11] [Cited by in Crossref: 54] [Cited by in F6Publishing: 17] [Article Influence: 5.4] [Reference Citation Analysis]
302 Jennings CL, Sherman KE. Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/AIDS Rep 2012;9:231-7. [PMID: 22638982 DOI: 10.1007/s11904-012-0122-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
303 Chastain CA, Naggie S. Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. Curr HIV/AIDS Rep. 2013;10:408-419. [PMID: 24272069 DOI: 10.1007/s11904-013-0182-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
304 Rockstroh JK, Yazdanpanah Y. HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges? J Antimicrob Chemother 2019;74:v2-4. [PMID: 31782498 DOI: 10.1093/jac/dkz447] [Reference Citation Analysis]
305 Adiwijaya BS, Kieffer TL, Henshaw J, Eisenhauer K, Kimko H, Alam JJ, Kauffman RS, Garg V. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol 2012;8:e1002339. [PMID: 22241977 DOI: 10.1371/journal.pcbi.1002339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
306 Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011;86:1009-26. [PMID: 21964179 DOI: 10.4065/mcp.2011.0309] [Cited by in Crossref: 137] [Cited by in F6Publishing: 106] [Article Influence: 13.7] [Reference Citation Analysis]
307 Hull M, Shafran S, Tseng A, Giguère P, Klein MB, Cooper C. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Can J Infect Dis Med Microbiol 2014;25:311-20. [PMID: 25587293 DOI: 10.1155/2014/251989] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
308 deLemos AS, Schmeltzer PA, Russo MW. Recurrent hepatitis C after liver transplant. World J Gastroenterol 2014; 20(31): 10668-10681 [PMID: 25152571 DOI: 10.3748/wjg.v20.i31.10668] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
309 Barritt AS 4th, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012;142:1314-1323.e1. [PMID: 22537438 DOI: 10.1053/j.gastro.2012.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
310 Strazzulla A, Costa C, Pisani V, De Maria V, Giancotti F, Di Salvo S, Parisi SG, Basso M, Franzetti MM, Marascio N, Liberto MC, Barreca GS, Lamberti AG, Zicca E, Postorino MC, Matera G, Focà A, Torti C. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. BMC Infect Dis 2014;14 Suppl 5:S3. [PMID: 25236374 DOI: 10.1186/1471-2334-14-S5-S3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
311 Thorlund K, Druyts E, El Khoury AC, Mills EJ. Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. Clinicoecon Outcomes Res 2012;4:349-59. [PMID: 23180971 DOI: 10.2147/CEOR.S37205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
312 Sweeney NL, Shadrick WR, Mukherjee S, Li K, Frankowski KJ, Schoenen FJ, Frick DN. Primuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis. J Biol Chem 2013;288:19949-57. [PMID: 23703611 DOI: 10.1074/jbc.M113.463166] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
313 Tao YL, Tang YF, Qiu JP, Cai XF, Shen XT, Wang YX, Zhao XT. Prevalence of hepatitis C infection among intravenous drug users in Shanghai. World J Gastroenterol 2013; 19(32): 5320-5325 [PMID: 23983436 DOI: 10.3748/wjg.v19.i32.5320] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
314 Ortiz V, Wands JR. Chronic ethanol diet increases regulatory T-cell activity and inhibits hepatitis C virus core-specific cellular immune responses in mice. Hepatol Res 2014;44:788-97. [PMID: 23710581 DOI: 10.1111/hepr.12173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
315 Wehmeyer MH, Eißing F, Jordan S, Röder C, Hennigs A, Degen O, Hüfner A, Hertling S, Schmiedel S, Sterneck M. Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterol. 2014;14:87. [PMID: 24884400 DOI: 10.1186/1471-230x-14-87] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
316 Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: Terminator of hepatitis C virus? World J Gastroenterol 2013; 19(21): 3199-3206 [PMID: 23745021 DOI: 10.3748/wjg.v19.i21.3199] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
317 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
318 Wang Y. Scotomas in molecular virology and epidemiology of hepatitis C virus. World J Gastroenterol 2013; 19(44): 7910-7921 [PMID: 24307785 DOI: 10.3748/wjg.v19.i44.7910] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
319 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
320 Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18(42): 6060-6069 [PMID: 23155334 DOI: 10.3748/wjg.v18.i42.6060] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
321 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19(41): 6947-6956 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
322 Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother. 2012;56:271-279. [PMID: 22064535 DOI: 10.1128/aac.05636-11] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
323 Hamada Y, Kiso Y. New directions for protease inhibitors directed drug discovery. Biopolymers 2016;106:563-79. [PMID: 26584340 DOI: 10.1002/bip.22780] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
324 Belle A, Gizard E, Conroy G, Lopez A, Bouvier-Alias M, Rouanet S, Peyrin-Biroulet L, Pawlotsky JM, Bronowicki JP. 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. United European Gastroenterol J 2017;5:69-75. [PMID: 28405324 DOI: 10.1177/2050640616640157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
325 Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, Akter S, Lee SK, Maeng CH, Baik HH, Kang I, Ha J, Kim SS. Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. Int J Nanomedicine 2015;10:903-21. [PMID: 25673987 DOI: 10.2147/IJN.S74723] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
326 Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One. 2012;7:e39652. [PMID: 22792183 DOI: 10.1371/journal.pone.0039652] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
327 Rong L, Guedj J, Dahari H, Perelson AS. Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Antivir Ther. 2014;19:469-477. [PMID: 24434478 DOI: 10.3851/imp2725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
328 Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, Miyamura T, Maruoka D, Wu S, Tanaka T. Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy. Int J Med Sci. 2013;10:43-49. [PMID: 23289004 DOI: 10.7150/ijms.5358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
329 Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-449. [PMID: 23140245 DOI: 10.1146/annurev-pharmtox-011112-140254] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
330 Mukherjee S, Weiner WS, Schroeder CE, Simpson DS, Hanson AM, Sweeney NL, Marvin RK, Ndjomou J, Kolli R, Isailovic D, Schoenen FJ, Frick DN. Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem Biol 2014;9:2393-403. [PMID: 25126694 DOI: 10.1021/cb500512z] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
331 Ndjomou J, Kolli R, Mukherjee S, Shadrick WR, Hanson AM, Sweeney NL, Bartczak D, Li K, Frankowski KJ, Schoenen FJ, Frick DN. Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation. Antiviral Res 2012;96:245-55. [PMID: 22940425 DOI: 10.1016/j.antiviral.2012.08.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
332 Kłujszo E, Parcheta P, Zarębska-Michaluk D, Ochwanowska E, Witkowska A, Rakowska A, Rudnicka L, Kryczka W. Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. J Dermatol Case Rep 2014;8:95-102. [PMID: 25621089 DOI: 10.3315/jdcr.2014.1183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
333 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
334 Komur S, Kurtaran B, Inal AS, Pullukcu H, Ulu A, Kuscu F, Yamazhan T, Tasova Y, Aksu HS. Telaprevir experience from Turkey. Hepat Mon 2015;15:e25639. [PMID: 25788959 DOI: 10.5812/hepatmon.25639] [Reference Citation Analysis]
335 Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clin Pharmacokinet 2016;55:275-95. [PMID: 26330025 DOI: 10.1007/s40262-015-0317-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
336 Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother 2014;58:1136-45. [PMID: 24295986 DOI: 10.1128/AAC.01515-13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
337 Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848 [PMID: 26668696 DOI: 10.4254/wjh.v7.i28.2841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
338 Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, Colby CL, Canterbury K, Warner J, Therneau TM. Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc 2014;89:595-601. [PMID: 24661475 DOI: 10.1016/j.mayocp.2014.01.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
339 Dieterich D, Asselah T, Guyader D, Berg T, Schuchmann M, Mauss S, Ratziu V, Ferenci P, Larrey D, Maieron A, Stern JO, Ozan M, Datsenko Y, Böcher WO, Steinmann G. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. Antimicrob Agents Chemother 2014;58:3429-36. [PMID: 24709256 DOI: 10.1128/AAC.02497-13] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
340 Andreev IA, Manvar D, Barreca ML, Belov DS, Basu A, Sweeney NL, Ratmanova NK, Lukyanenko ER, Manfroni G, Cecchetti V, Frick DN, Altieri A, Kaushik-Basu N, Kurkin AV. Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. Eur J Med Chem 2015;96:250-8. [PMID: 25890075 DOI: 10.1016/j.ejmech.2015.04.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
341 Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol 2015; 7(5): 806-813 [PMID: 25914781 DOI: 10.4254/wjh.v7.i5.806] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
342 Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol 2014; 20(23): 7079-7088 [PMID: 24966581 DOI: 10.3748/wjg.v20.i23.7079] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
343 Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014;73:831-7. [PMID: 23606708 DOI: 10.1136/annrheumdis-2012-202770] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
344 Braun M, Sharon E, Unterman I, Miller M, Shtern AM, Benenson S, Vainstein A, Tabach Y. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic. iScience 2020;23:101384. [PMID: 32738617 DOI: 10.1016/j.isci.2020.101384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
345 DiNicolantonio JJ, Bhutani J, O'Keefe JH. The health benefits of vitamin K. Open Heart 2015;2:e000300. [PMID: 26468402 DOI: 10.1136/openhrt-2015-000300] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
346 Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Ann Gastroenterol 2017;30:327-43. [PMID: 28469364 DOI: 10.20524/aog.2017.0136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
347 Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 2015;62:286-293. [PMID: 25218788 DOI: 10.1016/j.jhep.2014.08.052] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 10.1] [Reference Citation Analysis]
348 Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20(43): 15992-16013 [PMID: 25473152 DOI: 10.3748/wjg.v20.i43.15992] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
349 Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol 2015; 21(38): 10749-10759 [PMID: 26478667 DOI: 10.3748/wjg.v21.i38.10749] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
350 Bellanti F, Vendemiale G, Altomare E, Serviddio G. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol 2012;2012:849373. [PMID: 22966241 DOI: 10.1155/2012/849373] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
351 Thompson A, Devine S, Kattan M, Muir A. Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. PLoS One 2014;9:e103370. [PMID: 25084272 DOI: 10.1371/journal.pone.0103370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
352 Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol 2013; 19(47): 8963-8973 [PMID: 24379621 DOI: 10.3748/wjg.v19.i47.8963] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
353 Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55:1620-1628. [PMID: 22331658 DOI: 10.1002/hep.25653] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 11.4] [Reference Citation Analysis]
354 Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:713-728. [PMID: 24019151 DOI: 10.1038/nrgastro.2013.163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
355 Larrat S, Kulkarni O, Claude JB, Beugnot R, Blum MG, Fusillier K, Lupo J, Tremeaux P, Plages A, Marlu A, Duborjal H, Signori-Schmuck A, Francois O, Zarski JP, Morand P, Leroy V. Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients. J Clin Microbiol 2015;53:389-97. [PMID: 25411182 DOI: 10.1128/JCM.02547-14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
356 Sato M, Maekawa S, Komatsu N, Tatsumi A, Miura M, Muraoka M, Suzuki Y, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Uetake T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J Virol. 2015;89:6105-6116. [PMID: 25810555 DOI: 10.1128/jvi.03127-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
357 Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res. 2015;6:301-310. [PMID: 26257927 DOI: 10.1016/j.jare.2014.11.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
358 Manns MP, von Hahn T. Novel therapies for hepatitis C — one pill fits all? Nat Rev Drug Discov 2013;12:595-610. [DOI: 10.1038/nrd4050] [Cited by in Crossref: 140] [Cited by in F6Publishing: 130] [Article Influence: 17.5] [Reference Citation Analysis]
359 Jo YM, Lee SW, Han SY, Baek YH, Kim SY, Kim WJ, Ahn JH, Lee JY. Retreatment with peginterferon and ribavirin in chronic hepatitis C. World J Gastroenterol 2015; 21(6): 1994-1999 [PMID: 25684969 DOI: 10.3748/wjg.v21.i6.1994] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
360 Callefi LA, Villela-Nogueira CA, de Barros Tenore S, Carnaúba-Júnior D, Coelho HSM, Pinto PTA, Nabuco LC, Pessoa MG, Ferraz MLCG, Ferreira PRA, de Lourdes Candolo Martinelli A, Chachá SGF, de Souza Paiva Ferreira A, de Macedo Bisio AP, Brandão-Mello CE, Álvares-Da-Silva MR, Reuter T, Ivantes CAP, de Mello Perez R, Mendes-Correa MCJ. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics (Sao Paulo) 2017;72:378-85. [PMID: 28658438 DOI: 10.6061/clinics/2017(06)08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
361 Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 2012;206:654-61. [PMID: 22740714 DOI: 10.1093/infdis/jis410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
362 Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8:e58380. [PMID: 23505497 DOI: 10.1371/journal.pone.0058380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
363 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
364 Li S, Xing X, Yang Q, Xu H, He J, Chen Z, Zhu H. The effects of hepatitis C virus core protein on the expression of miR-122 in vitro. Virol J 2013;10:98. [PMID: 23537271 DOI: 10.1186/1743-422X-10-98] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
365 Pol S, Corouge M, Sogni P. Oral antiviral therapies for chronic hepatitis C infection. Ther Adv Infect Dis. 2013;1:107-116. [PMID: 25165547 DOI: 10.1177/2049936113488359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
366 Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis 2013;207 Suppl 1:S26-32. [PMID: 23390302 DOI: 10.1093/infdis/jis764] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
367 Varunok P, Lawitz E, Beavers KL, Matusow G, Leong R, Lambert N, Bernaards C, Solsky J, Brennan BJ, Wat C, Bertasso A. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient Prefer Adherence 2011;5:587-99. [PMID: 22163158 DOI: 10.2147/PPA.S26566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
368 Watanabe T, Joko K, Seike H, Michitaka K, Horiike N, Kisaka Y, Tanaka Y, Nakanishi S, Nakanishi K, Nonaka T, Yamauchi K, Onji M, Ohno Y, Tokumoto Y, Hirooka M, Abe M, Hiasa Y. Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. Springerplus 2016;5:518. [PMID: 27186482 DOI: 10.1186/s40064-016-2190-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
369 Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444. [PMID: 21898493 DOI: 10.1002/hep.24641].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
370 Talavera Pons S, Lamblin G, Boyer A, Sautou V, Abergel A. Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol 2014;70:775-89. [PMID: 24817413 DOI: 10.1007/s00228-014-1679-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
371 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 12.7] [Reference Citation Analysis]
372 Mathur P, Kottilil S, Wilson E. Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. J Clin Transl Hepatol 2018;6:431-7. [PMID: 30637222 DOI: 10.14218/JCTH.2018.00007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
373 Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 2015;61:1523-32. [PMID: 25644279 DOI: 10.1002/hep.27705] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 11.2] [Reference Citation Analysis]
374 Garcia-Rivera JA, Lin K, Hopkins S, Gregory MA, Wilkinson B, Gallay PA. Development of a flow cytometry live cell assay for the screening of inhibitors of hepatitis C virus (HCV) replication. Open Virol J 2012;6:97-102. [PMID: 23230455 DOI: 10.2174/1874357901206010097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
375 Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482-496. [PMID: 23748342 DOI: 10.1038/nrmicro3046] [Cited by in Crossref: 262] [Cited by in F6Publishing: 239] [Article Influence: 32.8] [Reference Citation Analysis]
376 Zhang EZ, Bartels DJ, Frantz JD, Seepersaud S, Lippke JA, Shames B, Zhou Y, Lin C, Kwong A, Kieffer TL. Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples. Virol J 2013;10:53. [PMID: 23402332 DOI: 10.1186/1743-422X-10-53] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
377 Burton JR, O’Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014;61:508-514. [PMID: 24801415 DOI: 10.1016/j.jhep.2014.04.037] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
378 Druyts E, Thorlund K, Humphreys S, Lion M, Cooper CL, Mills EJ. Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clin Epidemiol 2013;5:173-83. [PMID: 23843702 DOI: 10.2147/CLEP.S44273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
379 Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, Kottilil S. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016;23:496-505. [PMID: 26840694 DOI: 10.1111/jvh.12510] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
380 Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver. 2014;8:471-479. [PMID: 25228970 DOI: 10.5009/gnl14083] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
381 Kim AY. Management algorithm for genotype 1 hepatitis C virus. F1000Prime Rep 2013;5:24. [PMID: 23864931 DOI: 10.12703/P5-24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
382 Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75. [PMID: 22720279 DOI: 10.1155/2012/947676] [Cited by in Crossref: 40] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
383 Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav 2013;17:94-103. [PMID: 22907288 DOI: 10.1007/s10461-012-0288-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
384 Bichoupan K, Dieterich DT. Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs 2014;74:951-61. [PMID: 24866024 DOI: 10.1007/s40265-014-0232-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
385 Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015;64:483-94. [PMID: 24848265 DOI: 10.1136/gutjnl-2013-306155] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 9.6] [Reference Citation Analysis]
386 宁钢, 林潮双. 慢性丙型肝炎抗病毒治疗的历史和未来. 世界华人消化杂志 2016; 24(14): 2117-2130 [DOI: 10.11569/wcjd.v24.i14.2117] [Reference Citation Analysis]
387 Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011;29:993-1003. [PMID: 22068541 DOI: 10.1038/nbt.2020] [Cited by in Crossref: 203] [Cited by in F6Publishing: 173] [Article Influence: 20.3] [Reference Citation Analysis]
388 Nucara S, Caroleo B, Guadagnino V, Perrotti N, Trapasso F. Natural history and clinical response: "it's the virus, stupid, or is it the host?". BMC Infect Dis. 2012;12 Suppl 2:S6. [PMID: 23173731 DOI: 10.1186/1471-2334-12-S2-S6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
389 Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol 2013;8:1469-78. [PMID: 23594083 DOI: 10.1021/cb400100g] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
390 Thomas XV, de Bruijne J, Sullivan JC, Kieffer TL, Ho CK, Rebers SP, de Vries M, Reesink HW, Weegink CJ, Molenkamp R. Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir. PLoS One. 2012;7:e41191. [PMID: 22848441 DOI: 10.1371/journal.pone.0041191] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
391 González-Moreno J, Payeras-Cifre A. Hepatitis C virus infection: looking for interferon free regimens. ScientificWorldJournal. 2013;2013:825375. [PMID: 23710151 DOI: 10.1155/2013/825375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
392 Berger KL, Scherer J, Ranga M, Sha N, Stern JO, Quinson AM, Kukolj G. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. Antimicrob Agents Chemother 2015;59:6017-25. [PMID: 26195509 DOI: 10.1128/AAC.00932-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]